Summary of EGFR-Biomarker data from the randomized, controlled phase 3 trial SQUIRE on adding Necitumumab to first-line Gemcitabine-Cisplatin (GC) for squamous Non-Small Cell Lung Cancer (sqNSCLC).
Schumann, C Reck, M Thomas, M Mezger, J Socinski, M Hozak, R Depenbrock, H Krause, T Hirsch, F Thatcher, Nick
Schumann, C
Reck, M
Thomas, M
Mezger, J
Socinski, M
Hozak, R
Depenbrock, H
Krause, T
Hirsch, F
Thatcher, Nick
Citations
Altmetric:
Abstract
Description
Date
2017
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Summary of EGFR-Biomarker data from the randomized, controlled phase 3 trial SQUIRE on adding Necitumumab to first-line Gemcitabine-Cisplatin (GC) for squamous Non-Small Cell Lung Cancer (sqNSCLC). 2017, 40:31-31 Oncol Res Treat